Boxed warning on heart failure risk on diabetes drug label, says FDA

Diabetes :: Boxed warning on heart failure risk on diabetes drug label, says FDA

The U.S. Food and Drug Administration announced manufacturers of certain drugs approved to treat Type 2 diabetes have agreed to add a stronger warning on the risk of heart failure, a condition that occurs when the heart does not adequately pump blood.

The information will be included in the form of a "boxed" warning?FDA's strongest form of a warning.

The upgraded warning emphasizes that the drugs may cause or worsen heart failure in certain patients.

After a review of postmarketing adverse event reports, FDA determined that an updated label with a boxed warning on the risks of heart failure was needed for the entire thiazolidinedione class of antidiabetic drugs. This class includes Avandia (rosiglitazone), Actos (pioglitazone) Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepride). These drugs are used in conjunction with diet and exercise, to improve blood sugar control in adults with type 2 (non-insulin-dependent) diabetes. FDA had asked the drug's manufacturers, GlaxoSmithKline and Takeda, to address these concerns.

"Under FDA's postmarketing surveillance program, we carefully monitor new safety information for marketed drugs and take appropriate action when necessary to inform patients and health care providers of new information," said Steven Galson, M.D., M.P.H., director of FDA's Center for Drug Evaluation and Research. "This new boxed warning addresses FDA's concerns that despite the warnings and information already listed in the drug labels, these drugs are still being prescribed to patients without careful monitoring for signs of heart failure."

FDA's review of adverse event reports found cases of significant weight gain and edema?warning signs of heart failure. In some reports, FDA noted, continuation of therapy has been associated with poor outcomes, including death.

The strengthened warning advises health care professionals to observe patients carefully for the signs and symptoms of heart failure, including excessive, rapid weight gain, shortness of breath, and edema after starting drug therapy. Patients with these symptoms who then develop heart failure should receive appropriate management of the heart failure and use of the drug should be reconsidered. People who have questions should contact their health care providers to discuss alternative treatments.

The warning also states that these drugs should not be used by people with serious or severe heart failure who have marked limits on their activity and who are comfortable only at rest or who are confined to bed or a chair.

FDA's review of Avandia and possible increased risk of heart attacks is ongoing. On July 30, 2007, FDA's Endocrine and Metabolic Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommended that Avandia continue to be marketed, and further recommended that information be added to the labeling for risk of heart attacks (ischemic risks).




(Diabetes :: Boxed warning on heart failure risk on diabetes drug label, says FDA published at SpiritIndia on Tuesday, August 14, 2007)

Diabetes

Search more information on Diabetes, Diabetes books

Recently posted related articles on Diabetes :

1. Diabetes :: 63 percent of diabetics risk serious foot problems by wearing the wrong-sized shoes
2. Diabetes :: India to launch special programme to control diabetes
3. Diabetes :: Stanford researchers shed light on gestational diabetes
4. Diabetes :: The new source of islet cells
5. Diabetes :: European Medicine Agency confirms positive Avandia benefit risk assessment
6. Pancreatitis :: Diabetes drug Byetta, exenatide may cause acute pancreatitis
7. Diabetes :: PGC-1-alpha helps skeletal muscle and pancreatic islets communicate
8. Blood Pressure :: Women with high or increasing blood pressure are up to three times more likely to develop diabetes
9. Diabetes :: New IDF guidelines raise importance of post-meal glucose control
10. Diabetes :: Solving a critical part of the insulin puzzle

Most related articles:

- Diabetes :: Boxed warning on heart failure risk on diabetes drug label, says FDA
- Diabetes :: Takeda Revises diabetes drug Actos prescribing label - 20.5
- Avandia :: Glaxo updates prescribing information for Avandia in US - 19.4
- Diabetes :: Diabetes triples risk of heart failure for women - 13.1
- Heart Failure :: Diabetes drugs increase risk of heart failure - 12.6
- Diabetes :: Long-term use of diabetes drug increases heart attack risk by more than 40 percent - 12.2
- Asthma :: Genentech's Xolair asthma drug label warning - 12.1
- Diabetes :: Diabetes and Heart Failure Is Double Trouble for Older Women - 12
- Diabetes :: FDA has requested black box warnings for two diabetes medications - 11.7
- Diabetes :: FDA Knew of Avandia's Dangers Nearly Five Years Ago, Memo Shows - 10.7

Diabetes - recent related articles/news stories:

- Gene Deaf1 may play a role in type 1 diabetes
- Pancreatic cancer risk reduced by diabetes drug metformin
- Low birth weight linked to diabetes gene CDKAL1
- Treating obesity with brown fat in the body
- Antipsychotics raise blood sugar in older diabetes patients

»»   Colon Cancer :: Diet high in meat, fat, refined grains linked to colon cancer recurrence risk
««   Life :: US slips to 42nd position in life expectancy

Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Glossary | List

AYUSH = Ayurveda - Yoga - Unani - Siddha - Homeopathy -- Health articles

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com